AIM ImmunoTech(US:AIM) Globenewswire·2025-08-06 13:00Core Insights - AIM ImmunoTech Inc. will present significant clinical advancements of its drug Ampligen at the 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care in Warsaw, Poland, focusing on pancreatic cancer and other solid tumors [1][2] - The presentations will include data from the ongoing Phase 2 clinical trial for pancreatic cancer and the positive therapeutic effects of Ampligen on endometriosis, which is linked to ovarian cancer [1][3] Oncology - AIM will showcase data from its pancreatic cancer Early Access Program and the Phase 2 clinical trial at Erasmus Medical Center, highlighting the DURIPANC study that evaluates the combination of Ampligen and AstraZeneca's durvalumab for late-stage metastatic pancreatic cancer [3][4] - Preliminary results from the DURIPANC study indicate that Ampligen is well-tolerated, with promising early signs of improved progression-free survival (PFS) and overall survival (OS) compared to historical data [4][6] - Dr. Kalinski will discuss Ampligen's efficacy in treating various solid tumors, including late-stage recurrent ovarian cancer and triple-negative breast cancer, emphasizing the unmet healthcare needs these therapies address [5] Endometriosis - The upcoming presentation on endometriosis will analyze data from AIM's clinical trials for Chronic Fatigue Syndrome, revealing that approximately 80% of female participants experienced symptom improvement, highlighting Ampligen's potential in treating endometriosis [7][9] - Endometriosis affects around 190 million women globally and is associated with chronic pain and infertility, underscoring the need for new treatment options beyond radical surgeries [8] Company Overview - AIM ImmunoTech Inc. is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, with Ampligen being a first-in-class investigational drug that acts as a TLR3 agonist [10]